menu
    • menu
    [{"orgOrder":0,"company":"Nanoform","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Piroxicam","moa":"COX","graph1":"Immunology","graph2":"Preclinical","graph3":"Nanoform","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Nanoform \/ Quotient Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Nanoform \/ Quotient Sciences"},{"orgOrder":0,"company":"Nanoform","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Piroxicam","moa":"COX","graph1":"Immunology","graph2":"Phase I","graph3":"Nanoform","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral immediate release","sponsorNew":"Nanoform \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nanoform \/ Not Applicable"},{"orgOrder":0,"company":"Nanoform","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Piroxicam","moa":"COX","graph1":"Immunology","graph2":"Phase I","graph3":"Nanoform","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nanoform \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nanoform \/ Not Applicable"},{"orgOrder":0,"company":"Nanoform","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Piroxicam","moa":"COX-1","graph1":"Neurology","graph2":"Phase I","graph3":"Nanoform","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Immediate-release Tablet","sponsorNew":"Nanoform \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nanoform \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Piroxicam

    Menu

    Piroxicam

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nanoform

                            Finland arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Nanoform

                            Finland arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Piroxicam

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nanoform's Final Clinical Results Confirm Value Proposition to the Pharma Industry

                            Details : The primary objective of the study was to determine the PK and relative bioavailability of piroxicam following oral administration of single 20 mg nanoformed piroxicam IR tablets and reference product Felden 20mg tablets (Pfizer) in healthy subjects in t...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 18, 2021

                            Lead Product(s) : Piroxicam

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Nanoform

                            Finland arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Nanoform

                            Finland arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Piroxicam

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nanoform's Clinical Study Indicates Positive Interim Results

                            Details : Nanoform has received interim study results related to its Phase 1, Study designed to evaluate the pharmacokinetic profile of Piroxicam following administration of Nanoformed oral immediate release Piroxicam tablet and an IR reference product in healthy ...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 22, 2021

                            Lead Product(s) : Piroxicam

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Nanoform

                            Finland arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Nanoform

                            Finland arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Piroxicam

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nanoform Finland Reports First Dosing of Nanoformed Drug Successfully Accomplished

                            Details : First full cohort of twelve healthy volunteers has during the weekend at Quotient Sciences’ facilities in Nottingham, UK, been successfully dosed in the first ever phase 1 human trial of a nanoformed drug candidate using Nanoform’s proprietary CESS®...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 21, 2020

                            Lead Product(s) : Piroxicam

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Nanoform

                            Finland arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Nanoform

                            Finland arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Piroxicam

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Quotient Sciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nanoform Initiates GMP Campaign for First-in-Human Trial of Nanoformed Drug by year End

                            Details : In the clinical trial, Nanoform will investigate the behavior of an oral immediate release (IR) nanoformed formulation of piroxicam, an anti-inflammatory drug.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 20, 2020

                            Lead Product(s) : Piroxicam

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Quotient Sciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth